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Volume 49, Number 4 Blankensteijn et al 849cable to most patients, could significantly expand the justi-
fied use of EVAR for aneurysm treatment. Follow-up reg-
imens post-EVAR continue to be refined, with a clear trend
toward readily available office-based testing. The wider
application of aneurysm sac pressure sensors is expected to
enhance the safety of follow-up without CT but awaits
further confirmation.19 However, even if the setting of
collapsed nonpressurized sacs, it may be prudent to con-
tinue obtaining a CT scan every 5 years to detect new
remote aneurysms.20
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One important disadvantage of endovascular aneurysm repair
(EVAR) is the requirement for intense and lifelong surveillance. Dr
Chaer et al have put this assumption to the test in a retrospective
analysis of outcomes after EVAR in a selection of patients with a
shrinking or stable aneurysm sac in whom follow-up was switched
to color duplex ultrasound (CDU) imaging as the sole surveillance
method. They conclude that CDU-only surveillance is safe in these
patients and that it can be applied in almost all patients by 3 years
postoperatively. There are several reasons why these conclusions
must be interpreted with caution.
First, the reported safety is established in a highly selectedthe previous (elaborate) follow-up protocol and after having been
scrutinized and treated for endoleak: in short, successful EVAR
patients.
Furthermore, the selection criteria for CDU-only surveillance
were expanded after 1 year, skewing the study population. The
early switchers were predominantly long-term successful Ancure
(Guidant, Minneapolis, Minn) patients. Although this device is no
longer commercially available, it was shown to lead to early and
considerable sac shrinkage and to be durable. Conversely, the late
switchers were the patients with the newer endografts—mainly
Excluder (W. L. Gore and Assoc, Flagstaff, Ariz) and Zenith (Cook
Inc, Bloomington, Ind)—and therefore had shorter follow-up
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overall 4500 patient-months of follow-up after the switch com-
pared with 550 months for the Excluder and 1200 months for the
Zenith. Even more impressive is the difference in follow-up before
the switch: around 4000 patient-months for Ancure, about 800 for
Excluder, and 1000 for Zenith. So, the conclusion that CDU-only
follow-up is safe mainly pertains to patients who can be considered
successful EVAR cases 4 years after implantation of an Ancure
endograft. There is relatively little evidence this is true for the other
endografts.
With respect to the 97% “virtual” applicability at 3 years, I
note that only half were actually switched to CDU-only. Extrapo-
lation of safety may not be appropriate here.
It is not clear if endoleak should be the main objective of
long-term EVAR follow-up. Many authors believe size is a more
important indicator of failure, and CDU imaging has been shown
to be less sensitive for size changes than computed tomography.Finally, the authors make no mention of the value of plain
abdominal films. This follow-up modality has many of the advan-
tages of CDU imaging and also produces more objective results.
Long-term concerns mainly pertain to device (metal or fabric)
failures, and CDU imaging can only be expected to diagnose the
consequences of these failures, whereas plain films might diagnose
problems before consequences actually arise. Therefore, a follow-up
protocol with both CDU imaging and plain abdominal films may
even be safer than only CDU imaging, without many extra risks
and costs.
Owing to the low incidence of treatment failure with the
currently available endografts, large and long-term prospective
studies are required to prove whether one can safely switch to a
CDU-only follow-up policy, or even stop active surveillance en-
tirely. With the described restrictions in mind, Dr Chaer and
colleagues should be congratulated for their provocative and first-
time report of outcomes of a minimized follow-up regimen.
